BIO Stock Overview
Develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Biotest Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €41.00 |
| 52 Week High | €42.60 |
| 52 Week Low | €40.40 |
| Beta | 0.24 |
| 11 Month Change | 0% |
| 3 Month Change | -0.49% |
| 1 Year Change | -3.30% |
| 33 Year Change | -5.53% |
| 5 Year Change | 83.86% |
| Change since IPO | 325.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIO | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | -1.3% |
| 1Y | -3.3% | -17.5% | 7.4% |
Return vs Industry: BIO exceeded the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: BIO underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| BIO volatility | |
|---|---|
| BIO Average Weekly Movement | 1.4% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BIO has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BIO's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,464 | Peter Janssen | www.biotest.com |
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine.
Biotest Aktiengesellschaft Fundamentals Summary
| BIO fundamental statistics | |
|---|---|
| Market cap | €1.37b |
| Earnings (TTM) | €40.80m |
| Revenue (TTM) | €679.20m |
26.7x
P/E Ratio1.6x
P/S RatioIs BIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO income statement (TTM) | |
|---|---|
| Revenue | €679.20m |
| Cost of Revenue | €466.90m |
| Gross Profit | €212.30m |
| Other Expenses | €171.50m |
| Earnings | €40.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 28, 2025
| Earnings per share (EPS) | 1.03 |
| Gross Margin | 31.26% |
| Net Profit Margin | 6.01% |
| Debt/Equity Ratio | 116.4% |
How did BIO perform over the long term?
See historical performance and comparison